Pepscan Therapeutics is a biopharmaceutical company developing novel therapeutic options for a/o cancer and immunological diseases. Pepscan Therapeutics is applying its proprietary technology platform for the discovery and development of improved therapeutic peptides and monoclonal antibodies against intractable targets like GPCR's.
Pepscan’s high throughput CLIPS protein mimicking technology platform covers fast screening and efficient synthesis of conformationally constrained peptides, which opens up new avenues for peptide drug discovery. Pepscan’s protein mimicry capabilities have also led to a truly innovative way to unlock the full potential of antibodies against cell membrane integrated receptor targets (such as GPCRs and ion channels).
The value of Pepscan’s platform has been recognized by strategic partners, as demonstrated by a recent series of R&D collaborations with pharma and biotech companies both in the US and the EU.